Subject    don  t be the last one on this
stock finder newsletter wants to inform
aggressive investors of a company that we feel is extremely undervalued and
poised for growth 
 to  plus inc  otcbb  tttp 
fiscal year end  dec 
 week high    
shares outstanding   million
shares in the public float   million
target price in next    days         
target price in next  days     
the company
 to  plus  inc   otcbb  tttp  is a late stage development company that
produces and markets  through its neurochemical research group division  highly
effective condition  specific supplements  often referred to as neutraceuticals 
the products  manufactured by fda  approved labs  contain a sophisticated
combination of extensively researched nutritional elements and do not contain
herbs  retail sales in the explosive dietary supplement market are expected to
hit   billion by the year   according to frost sullivan reports 
marketing research  product development  beta testing and various mergers and
acquisitions in   has now positioned  to  plus  tttp  to roll out its
full product line consisting of  products of which they have their own
proprietary formula  into the multi  billion dollar over the counter  otc 
market   to  plus is ready to capitalize on its exceptional product line 
key facts about  to  plus inc
 they have introduced  products to the market that the company owns the
proprietary rights to  products that have been produced in fda approved labs 
 one of their products anaplex  antidepressant  is currently being sold and
distributed in longs drug stores  one of america  s leading drug stores with over
 stores
 the company is negotiating deals with two major distributors in europe for
their healthcare products 
 they are currently in process of attempting to market one their newest
products a revolutionary re  hydration product to the u  s military and to allied
forces overseas 
the industry
the neutraceutical sector has experienced some great growth over the past five
years  being capped off in  when revenues for the global nutrition markets
hit   billion  united states took responsibility for about    of that  with
    billion     coming from the nutrition markets      from functional
foods  and     billion from personal care products  it  s safe to say that
globally we are looking for new ways to live healthier and longer lives  and
that pharmaceutical remedies could quickly be a thing of the past 
it  s estimated that   of medical doctors  practices entail writing
pharmaceutical prescriptions and that   of these prescriptions are to treat
the side effects of medications being utilized to treat the specific ailment 
people are no longer neglecting the facts that what they are putting into their
bodies  may not be good for them  medicinal foods or nutritionally high powered
foods have been in the natural products industry for a long time and through
emerging scientific research the public interest has the reached the mainstream 
it seems as though everywhere you look these days the talk is on dieting whether
it be the low carbohydrate  high protein atkins diet  the zone diet  or any of
the other millions of options we have  the world is concerned with weight 
according to the american obesity association  of adults over the age of  in
the united states  million are overweight   million are obese  and 
million are severely obese  obesity increases the risk of illness from 
serious medical conditions  this fact is forcing many of the snack food and soft
drink companies to come up with new healthier products that meet the taste
standards of today  s consumers 
comparable companies in this sector
 usana health sciences inc  nasdaq  usna  current price    
 nutraceutical international corp  nasdaq  nutr  current price    
 vital living inc  otcbb  vtlv  current price   
disclaimer 
this contains forward  looking statements
within the meaning of the private securities litigation reform act of  
these statements may be identified by such terms as expect  believe  may 
will  explode  move  undervalued and intend or similar terms  the
information in the above statement could not be   accurate and the newsletter
is not responsible for this  we are not a registered investment advisor or a
broker dealer  this is not an offer to buy or sell securities  no recommendation
that the securities of the companies profiled should be purchased  sold or held
by individuals or entities that learn of the profiled companies  this newsletter
was paid   in cash by third   party to publish this report  investing in
companies profiled is high  risk and use of this information is for reading
purposes only  if anyone decides to act as an investor  then it will be that
investor  s sole risk  investors are advised not to invest without the proper
advertisement from an attorney or a registered financial broker  do not rely
solely on the information presented  do additional independent research to form
your own opinion and decision regarding investing in the profiled companies  be
advised that the purchase of such high  risk securities may result in the loss of
your entire investment  void where prohibited  the owners of this publication or
their partners may already own free trading shares in tttp and may immediately
sell all or a the time this date stated and are subject to change without
notice 
